GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

GSK PLC GSK shares advanced 3.35% to £14.02 Monday, on what proved to be an all-around great trading session for the stock ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

During Lacalle's meeting with British Prime Minister Boris Johnson, the launch of a sovereign bond linked to sustainability goals was discussed Pharmaceutical giant GlaxoSmithKline (GSK ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...

GSK plc and the University of Oxford (Oxford) announced that they have entered a new research collaboration focused on the potential of cancer prevention through vaccination. The GSK-Oxford Cancer ...

(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and ...

Shares of GSK PLC GSK inched down 0.51% to £13.57 Friday, on what proved to be an all-around poor trading session for the ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...